# A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis

> **NCT03275025** · PHASE2 · COMPLETED · sponsor: **Yungjin Pharm. Co., Ltd.** · enrollment: 116 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** YRA-1909 low dose
- **DRUG:** YRA-1909 mid dose
- **DRUG:** YRA-1909 high dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03275025
- **Lead sponsor:** Yungjin Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-01
- **Primary completion:** 2019-11-19
- **Final completion:** 2019-11-19
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2021-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03275025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03275025, "A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03275025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*